Keybanc Upgrades Exagen to Overweight, Maintains Price Target to $12
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
Keybanc analyst Paul Knight upgrades Exagen (NASDAQ:XGN) from Sector Weight to Overweight and maintains the price target from $12 to $12.
Keybanc analyst Paul Knight upgrades Exagen (NASDAQ:XGN) from Sector Weight to Overweight and maintains the price target from $12 to $12.